71 related articles for article (PubMed ID: 33715009)
1. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into IL-6 signaling inhibition by therapeutic antibodies.
Wang M; Chen L; He J; Xia W; Ye Z; She J
Cell Rep; 2024 Mar; 43(3):113819. PubMed ID: 38393945
[TBL] [Abstract][Full Text] [Related]
3. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
Kozma GT; Mészáros T; Bakos T; Hennies M; Bencze D; Uzonyi B; Győrffy B; Cedrone E; Dobrovolskaia MA; Józsi M; Szebeni J
Front Immunol; 2021; 12():642860. PubMed ID: 33995361
[TBL] [Abstract][Full Text] [Related]
4. Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.
Roshanravan N; Seif F; Ostadrahimi A; Pouraghaei M; Ghaffari S
Arch Med Res; 2020 Oct; 51(7):608-612. PubMed ID: 32682575
[TBL] [Abstract][Full Text] [Related]
5. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis.
Lu L; Zhang H; Dauphars DJ; He YW
Trends Immunol; 2021 Jan; 42(1):3-5. PubMed ID: 33214057
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies.
Elemam NM; Maghazachi AA; Hannawi S
Curr Med Res Opin; 2021 Jun; 37(6):929-938. PubMed ID: 33754931
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study.
Mastroianni A; Greco S; Apuzzo G; De Santis S; Oriolo C; Zanolini A; Chidichimo L; Vangeli V
EClinicalMedicine; 2020 Jul; 24():100410. PubMed ID: 32766535
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
Rossi JF; Chiang HC; Lu ZY; Levon K; van Rhee F; Kanhai K; Fajgenbaum DC; Klein B
Front Immunol; 2022; 13():919489. PubMed ID: 35928820
[TBL] [Abstract][Full Text] [Related]
9. Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an
Zarinsefat A; Hartoularos G; Rychkov D; Rashmi P; Chandran S; Vincenti F; Yee CJ; Sarwal MM
Front Genet; 2020; 11():610682. PubMed ID: 33469465
[TBL] [Abstract][Full Text] [Related]
10. NLRP3 Inflammasome Involvement in Heart, Liver, and Lung Diseases-A Lesson from Cytokine Storm Syndrome.
Napodano C; Carnazzo V; Basile V; Pocino K; Stefanile A; Gallucci S; Natali P; Basile U; Marino M
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068879
[TBL] [Abstract][Full Text] [Related]
11. New Advances in Viral and Microorganism Disinfectants.
Onodera T; Kirisawa R
Microorganisms; 2023 Oct; 11(10):. PubMed ID: 37894187
[TBL] [Abstract][Full Text] [Related]
12. Reactive arthritis following COVID-19 current evidence, diagnosis, and management strategies.
Migliorini F; Bell A; Vaishya R; Eschweiler J; Hildebrand F; Maffulli N
J Orthop Surg Res; 2023 Mar; 18(1):205. PubMed ID: 36922870
[TBL] [Abstract][Full Text] [Related]
13. [Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients.
Garcia-Molina A; Alos-Almiñana M
Farm Hosp; 2023; 47(1):T10-T15. PubMed ID: 36707309
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients.
Garcia-Molina A; Alós-Almiñana M
Farm Hosp; 2023; 47(1):10-15. PubMed ID: 36635189
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity to Biological Treatments in Juvenile Idiopathic Arthritis: How Should It Be Managed?
Kasap Cuceoglu M; Basaran O; Soyer O; Ozen S
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555908
[TBL] [Abstract][Full Text] [Related]
16. Identification of small molecules as potential inhibitors of interleukin 6: a multi-computational investigation.
Tran QH; Nguyen QT; Tran TN; Tran TD; Le MT; Trinh DT; Tran VT; Tran VH; Thai KM
Mol Divers; 2023 Oct; 27(5):2315-2330. PubMed ID: 36319930
[TBL] [Abstract][Full Text] [Related]
17. A promising antitumor method: Targeting CSC with immune cells modified with CAR.
Huang B; Miao L; Liu J; Zhang J; Li Y
Front Immunol; 2022; 13():937327. PubMed ID: 36032145
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Pathology on Various Organs and Regenerative Medicine and Stem Cell-Based Interventions.
Arjmand B; Alavi-Moghadam S; Parhizkar Roudsari P; Rezaei-Tavirani M; Rahim F; Gilany K; Mohamadi-Jahani F; Adibi H; Larijani B
Front Cell Dev Biol; 2021; 9():675310. PubMed ID: 34195193
[TBL] [Abstract][Full Text] [Related]
19. IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
Kishimoto T
Int Immunol; 2021 Sep; 33(10):515-519. PubMed ID: 33715009
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
